Diagnostic Direct DNA Sequencing and Systemic Treatment with Voriconazole in Scedosporium apiospermum Keratitis? A Case Report

Qiao Sun1, Xun Xu1, Qiang-qiang Zhang2, Hai-yan Wang1 and Yan Liu*1*

1Department of Ophthalmology, Shanghai First People’s Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China
2Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China

Abstract

Scedosporium apiospermum keratitis is a rare but challenging infection because of its high misidentification rate and resistance to many antifungal agents. A 35-year-old immunocompetent man with severe Scedosporium apiospermum keratitis diagnosed by both microbiology and DNA sequencing methods, which was successfully treated with systemic voriconazole was reported. Diagnosis and drug susceptibilities were discussed.

Keywords: Scedosporium apiospermum; Keratitis; Voriconazole; Drug susceptibility; DNA sequencing

Case Report

A 35-year-old Chinese man was referred to our hospital due to redness, decreased vision and gritty sensation in the left eye. His symptoms deteriorated despite topical and intravenous treatments (therapeutic regimen unknown) in a local hospital for 20 days. Physical examination and laboratory work-up were negative. Predisposing factors such as recent ocular injury, contact lens use, prior keratitis or immunosuppressed status were denied. His fellow eye, however, underwent a corneal foreign body extraction one year ago when he worked in a salvage station, and soon recovered to 20/20.

At presentation, best-corrected visual acuity was hand-motion in the left eye. There was a central, ring-shaped, 6 × 6 mm dense corneal abscess with adjacent cellular infiltration and a 4 mm hypopyon. Other details were not discernible. B ultrasound examination revealed a clear vitreous and no retinal detachment. Ophthalmic examination of the right eye was unremarkable except a small nebula compatible with the corneal foreign body extraction history mentioned above.

Fungal keratitis was diagnosed clinically. Primary microscopic examination of corneal scrapings found no bacteria or fungi. Further microbiology culture was conducted. Surgical debridement and empirical broad-spectrum treatment: intravenous voriconazole (loading dose of 6 mg/kg every 12 hours for day 1, 4 mg/kg every 12 hours from day 2-5), oral faropenem sodium 200 mg t.i.d., topical atropine t.i.d., levofloxacin 0.5%, natamycin 5% and dextran / hypromellose q.h. were commenced.

In the following days, corneal infiltration and hypopyon promptly declined (Figures 1a and 1b). On day 6, a second surgical debridement was performed; thereafter, voriconazole was shifted to orally 200 mg every 12 hours.

On day 7, the mycology culture revealed a growth of cottony whitish filamentous fungus (Figure 2a). Microscopy study revealed ovoid conidial structures at the top of conidiophores, some of which

Figure 1: Clinical photograph of the left eye. (a) 2 days after admission, corneal abscess and hypopyon are demonstrated. (b) 5 days after admission, infiltration decreased and hypopyon totally disappeared.

Figure 2: Microbiology photograph of the fungus. (a) 7 days after fungal culture on Sabouraud’s glucose agar, cottony whitish filamentous fungus could been seen. (b) Microscopy (X400). Ovoid conidial structures at the top of conidiophores, with some of them clearly separated from hyphae can be identified.
Discussion

*Scedosporium apiospermum*, the anamorph of the ascomycete *Pseudallescheria boydii*, is a world-wild saprophyte found in the soil, pounds, sewage and decaying plant. For eye affected cases, endophthalmitis patients are usually previously immunocompromised or have underlying pulmonary disease [1,2]. But for keratitis patients, predisposing factors such as contact lens wearing, ocular trauma, surgery, recurrent keratitis and multiple sclerosis are usually found [3-6]. In our case, no definite cause could be confirmed, although an unconscious injury was suspected, considering his occupation and the history of corneal foreign body extraction in his right eye.

*S. apiospermum* keratitis resembles other types of fungal keratitis in clinical presentations and microbiology findings [7]. The traditional identification approaches were sometimes problematic and time consuming. It was reported that when submitted to a panel of laboratories as an NEQAS quality control, a *S. apiospermum* isolate was misidentified by more than 40% of participants [8]. The delay in diagnosis and aggressive treatment makes it one of the species that most frequently lead to perforation [8], with evisceration or enucleation being the final result in 21% in 2003 [9]. In this circumstance, molecular method, which costs a shorter turnaround time but provides a result well parallel to traditional techniques [10], plays a promising role in timely diagnosis.

E-test method was proved to have a good level of agreement with the standard procedures proposed by NCCLS (the National Committee for Clinical Laboratory Standards) for the antifungal susceptibility testing. The E-test of our case indicated that the fungi was sensitive to caspofungin, voriconazole, fluconazole and itraconazole (MICs were 0.38 μg/ml, 0.008 μg/ml, 3 μg/ml, 0.5 μg/ml respectively), but resistant to amphotericin B. The results are in agreement with previous studies summarized in Table 1. These studies indicated that the most potent activity was observed with voriconazole, followed by miconazole, clearly separated from hyphae (Figure 2b). The isolate was submitted to a microbiology center for further identification. Meanwhile, a loopful of the colony was processed for DNA sequencing, which yielded a 99% homology with several sequences of *Scedosporium apiospermum*.

We discontinued oral faropenem sodium, and tapered topical levofloxacin 0.5% to b.i.d.. The inflammation was steadily controlled. Eighteen days later, microbiology center reported an identification of *Scedosporium apiospermum*, which was in concordance with the result of the DNA sequencing.

E-test for drug susceptibility was also performed. Minimal inhibitory concentrations (MICs) were determined after incubation at 35°C for 72 hours. MICs of caspofungin, voriconazole, fluconazole, itraconazole and amphotericin B were 0.38 μg/ml, 0.008 μg/ml, 3 μg/ml, 0.5 μg/ml and >32 μg/ml.

Since the infiltration was large and involving full-thickness corneal stroma, penetrating keratoplasty (PK) with glycerol preserved donor cornea was performed on day 13, iris neovascularization, central anterior synechia, exudative membrane and cataract were disclosed. Corneal button for microbiological examination (smear and culture) showed no growth of microorganism. Because corticosteroid was used after PK to prevent rejection, intravenous voriconazole and topical natamycin 5% were applied to prevent a relapse.

No adverse effect was encountered during the therapeutic regimen. Visual acuity of his left eye was hand-motion at discharge. Intensive follow up was recommended for further therapy like antiglaucoma surgery, cataract surgery and PK with fresh corneal graft.

| drug          | references | No. of strains | Method         | Incubation time (hours) | MIC, μg/ml |
|---------------|------------|----------------|----------------|-------------------------|------------|
| Albacozazole  | [11]       | 13             | M38-P          | 48                      | 0.03-1     |
| [11,12]      |            | 24             | M38-P          | 72                      | 0.06-2     |
| Amphotericin  | [13,14]    | 20             | E-test         | 48                      | 2->32      |
| [14]         |            | 10             | E-test         | 72                      | 4-8        |
| [13,15]      | 37         | M27-A          | 48              | 1->16                    | 4          |
| [16,17]      | 122        | M38-A          | 48              | 0.5-16                   | 4          |
| [11]         | 13         | M38-P          | 48              | 0.5-8                    | 1.72       |
| [11,12,14,18]| 51         | M38-P          | 72              | 1->16                    | 2.97-4     |
| [19]         | 26         | -              | -              | 1-6                     | 4.56       |
| Fluconazole   | [20]       | 10             | Sensititre     | 72                      | 2->16      |
| [20]         | 10         | Sensititre     | 72              | 16->256                 | -          |
| [15]         | 27         | M27-A          | 48              | 16->16                   | >16        |
| [18]         | 17         | M38-P          | 72              | 8->64                   | 16         |
| Itraconazole  | [16,17,21]| 176            | M38-A          | 48                      | 0.03->8.0  |
| [20]         | 10         | Sensititre     | 72              | 0.5->16                  | -          |
| [19]         | 26         | -              | -              | 0.125-2                 | 0.65       |
| [13,15]      | 37         | M27-A          | 48              | 0.25-16                  | -          |
| [13,14]      | 20         | E-test         | 48              | 0.25->32                | -          |
| [14]         | 10         | E-test         | 72              | 0.25->0.5               | -          |
| [11]         | 13         | M38-P          | 48              | 0.03-2                  | 0.35       |
posaconazole and albacinazole; amphotericin B; fluconazole and itraconazole showed variable antifungal activity; 5-Flucytosine did not have any antifungal activity.

Possessing a high level of _in vitro_ activity, posaconazole and albacinazole might be effective therapies, but so far as we know, applications of these agents in ophthalmology have not been reported. Miconazole, which seems to be a good choice for ophthalmologists, is associated with adverse effects like hypotension, pruritus, and bone marrow / hepatic toxicity [26]. Itraconazole, which is a good alternative in some cases (including our case), is poorly absorbed with oral administration [27].

Voriconazole demonstrated a favorable MIC, as well as an optimal bioavailability. It was reported that after 12 days of oral voriconazole, the mean concentration in plasma was 3.4 μg/ml, and 1.8 μg/ml (53% of the level in plasma) in the aqueous humor, which exceeded the MIC by sevenfold [28]. Side effects consist of fully reversible mild to moderate visual disturbances and elevated liver function enzymes [29], indicating a considerable safety. The formula of voriconazole 1% eye drop expanded ophthalmological treatment regimen for this refractory disease [30-32].

We reported a case with severe _S. apiospermum_ keratitis which was successfully treated with systemic administration of voriconazole. We identified the fungal species with microbiology and molecular method, and took a subsequent sensitivity test. In our opinion, repeated smear and culture are essential in microbiology examination, but DNA sequencing should be considered as an effective and efficient tool in fungal identification. As adjunctive therapy to surgical debridement, systemic and topical voriconazole are good choices.

| [11,12,14,18] | 51 | M38-P | 72 | 0.03->16 | 0.78-4.5 | 0.5->16 | 1->16 |
| [22] | 6 | - | - | 0.12->64 | - | - |
| Ketoconazole | [20] | 10 | Sensititre | 72 | 0.25->16 | - | - | ≥16 |
| [15] | 27 | M27-A | 48 | 0.06->16 | 2 | 2 | >16 |
| Liposomal nystatin | [11] | 13 | M38-P | 48 | 2-16 | 5.99 | 4 | 16 |
| [11] | 13 | M38-P | 72 | 4-16 | 11.99 | 16 | 16 |
| Miconazole | [15] | 27 | M27-A | 48 | 0.06-4 | 0.5 | 0.5 | 2 |
| [11] | 13 | M38-P | 48 | 0.125 | 0.34 | 0.25 | 1 |
| [11,18] | 30 | M38-P | 72 | ≤0.06-1 | - | 0.25-0.5 | 0.5-1 |
| Micafungin | [23] | 3 | M38-A | 24 | 0.25-128 | - | 32 |
| [18] | 17 | M38-P | 72 | 16->16 | - | >16 | >16 |
| Nystatin | [11,12] | 24 | M38-P | 72 | 4-32 | 12.70-13.24 | 4-16 | ≥16 |
| [11] | 13 | M38-P | 48 | 2-16 | 5.99 | - | - |
| Posaconazole | [19] | 20 | - | - | 0.25-1.0 | 0.57 | 0.5 | 1 |
| [17] | 65 | M38-A | 48 | - | - | 1.0 | 8.0 |
| [11] | 13 | M38-P | 48 | 0.125-1 | 0.42 | 0.5 | 1 |
| [11,12] | 24 | M38-P | 72 | 0.03-2 | 0.08-0.79 | 0.03-1 | 0.25-2 |
| Ravuconazole | [21] | 54 | M38-A | 48 | 0.5->8.0 | 3.8 | 4.0 | >8.0 |
| [12] | 11 | M38-P | 72 | 0.125 | 0.125 | 0.125 | 0.125 |
| Terbinafine | [19] | 5 | - | - | 32 | 32 | 32 | 32 |
| [24] | 31 | M38-A | 48 | 8->16 | 17.1 | - | >16 |
| [11] | 13 | M38-P | 48 | 2->32 | 32 | 32 | >32 |
| Voriconazole | [16,17,21] | 176 | M38-A | 48 | 0.06-4.0 | - | 0.25-1.0 | 0.25-4.0 | >8.0 |
| [19] | 26 | - | - | 0.06-1.0 | 0.22 | 0.25 | 0.25 |
| [15] | 27 | M27-A | 48 | 0.5-2 | 1 | 1 | 2 |
| [23,25] | 9 | M38-A | 72 | 0.125-1.0 | - | 0.125-0.5 | 0.25-1 |
| [11,12,18] | 44 | M38-P | 72 | 0.01-0.5 | 0.06-0.17 | 0.06-0.25 | 0.125-0.5 |
| [11] | 13 | M38-P | 48 | 0.03-0.5 | 0.09 | 0.125 | 0.25 |
| [22] | 6 | - | - | 0.12-0.5 |
| 5-Fluorocytosine | [20] | 10 | Sensititre | 72 | 4->64 | - | - | ≥64 |
| [15] | 27 | M27-A | 48 | >16 | >16 | >16 | >16 |
| [18] | 17 | M38-P | 72 | 8->64 | - | 16 | 32 |

Table 1: _In Vitro_ Drug Susceptibilities of _Scedosporium apiospermum_.

Citation: Sun Q, Xu X, Zhang Qq, Wang Hy, Liu Y (2013) Diagnostic Direct DNA Sequencing and Systemic Treatment with Voriconazole in _Scedosporium apiospermum_ Keratitis? A Case Report. J Clin Exp Ophthalmol 4: 299. doi: 10.4172/2155-9570.1000299
References

1. Jain A, Egbert P, McCulley TJ, Blumenkranz MS, Moshfeghi DM (2007) Endogenous Scedosporium apiospermum endophthalmitis. Arch Ophthalmol 125: 1286-1289.

2. Chen FK, Chen SD, Tay-Kearney ML (2007) Intravitreal voriconazole for the treatment of endogenous endophthalmitis caused by Scedosporium apiospermum. Clin Experiment Ophthalmol 35: 382-385.

3. Rumelt S, Cohen I, Leffler E, Rehany U (2001) Corneal co-infection with Scedosporium apiospermum and Acanthamoeba after sewage-contaminated ocular injury. Cornea 20: 112-116.

4. Wu Z, Ying H, Yu S, Irvine J, Smith R (2002) Fungal keratitis caused by Scedosporium apiospermum: report of two cases and review of treatment. Cornea 21: 519-523.

5. Singh RP, McCluskey P (2005) Scedosporium prolificans sclerokeratitis 10 years after pterygium excision with adjunctive mitomycin C. Clin Experiment Ophthalmol 33: 433-434.

6. Díaz-Valle D, Benitez del Castillo JM, Amor E, Toledano N, Carretero MM, et al. (2002) Severe keratomycosis secondary to Scedosporium apiospermum. Cornea 21: 516-518.

7. Guarro J, Kantarcıoğlu AS, Horre R, Rodríguez-Tudela JL, Cuenca Estrella M, et al. (2006) Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycol 44: 295-327.

8. Mancini N, Ossí CM, Perotti M, Carletti S, Gianni C, et al. (2005) Direct sequencing of Scedosporium apiospermum DNA in the diagnosis of a case of keratitis. J Med Microbiol 54: 897-900.

9. Thomas PA (2003) Current perspectives on ophthalmic mycoses. Clin Microbiol Rev 16: 730-797.

10. Fujita S, Senda Y, Nakaguchi S, Hashimoto T (2001) Multiplex PCR using internal transcribed spacer 1 and 2 regions for rapid detection and identification of yeast strains. J Clin Microbiol 39: 3617-3622.

11. Meletiadis J, Meis JF, Mouton JW, Rodriguez-Tudela JL, Donnelly JP, et al. (2002) In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 46: 62-68.

12. cCarrillo AJ, Guarro J (2001) In vitro activities of four novel triazoles against Scedosporium apiospermum spp. Antimicrob Agents Chemother 45: 2151-2153.

13. Székely A, Johnson EM, Warnock DW (1999) Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds. J Clin Microbiol 37: 1480-1483.

14. Espinel-Ingroff A (2001) Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin Microbiol 39: 1360-1367.

15. Cuenca-Estrella M, Ruiz-Díez B, Martínez-Suárez JV, Monzón A, Rodríguez-Tudela JL (1999) Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 43: 149-151.

16. Espinel-Ingroff A, Johnson E, Hockey H, Troke P (2008) Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother 61: 616-620.

17. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, et al. (2006) Head-to-head comparison of the activities of currently available antifungal agents against 3,376 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 50: 917-921.

18. Zeng J, Kamei K, Zheng Y, Nishimura K (2004) Susceptibility of Pseudallescheria boydii and Scedosporium apiospermum to new antifungal agents. Nihon Ishinkin Gakkai Zasshi 45: 101-104.

19. Heath CH, Slavin MA, Sorrell TC, Handike R, Harun A, et al. (2009) Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect 15: 689-693.

20. Carrillo-Muñoz AJ, Quindós G, Ruesga M, del Valle O, Pemán J, et al. (2006) In vitro antifungal susceptibility testing of filamentous fungi with Sensititre Yeast One. Mycoses 49: 293-297.

21. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Monzon A, et al. (2005) In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob Agents Chemother 49: 5136-5138.

22. Radford SA, Johnson EM, Warnock DW (1997) In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 41: 841-843.

23. Heyn K, Tredup A, Salvenmoser S, Müller FM (2005) Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 49: 5157-5159.

24. García-Effron G, Gomez-Lopez A, Mellado E, Monzon A, Rodriguez-Tudela JL, et al. (2004) In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi. J Antimicrob Chemother 53: 1086-1089.

25. Linares MJ, Charriel G, Solís F, Rodríguez F, Ibarra A, et al. (2005) Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods. J Clin Microbiol 43: 250-253.

26. Berenguer J, Rodríguez-Tudela JL, Richard C, Alvarez M, Sanz MA, et al. (1997) Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group. Medicine (Baltimore) 76: 256-265.

27. De Beule K (1996) Itraconazole: pharmacology, clinical experience and future development. Int J Antimicrob Agents 6: 175-181.

28. Nulens E, Eggink G, Rijks AJ, Wesseling P, Verweij PE (2003) Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole. J Clin Microbiol 41: 2261-2264.

29. Sabo JA, Abdel-Rahman SM (2000) Voriconazole: a new triazole antifungal. Ann Pharmacother 34: 1032-1043.

30. Hernández Prats C, Linares Tello F, Burgos San José A, Selva Otaolaurichi J, Ordováš Baines JP (2004) Voriconazole in fungal keratitis caused by Scedosporium apiospermum. Ann Pharmacother 38: 414-417.

31. Reis A, Sundmacher R, Tintelnot K, Agostini H, Jensen HE, et al. (2000) Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol 84: 932-933.

32. Al-Badiyyeh D, Leung L, Davies GE, Stewart K, Kong D (2009) Successful salvage treatment of Scedosporium apiospermum keratitis with topical voriconazole after failure of natamycin. Ann Pharmacother 43: 1139-1142.